Should I buy or sell Leap Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares. View LPTX analyst ratings or view top-rated stocks .

What is Leap Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $17.50. On average, they predict the company's share price to reach $11.38 in the next twelve months. This suggests a possible upside of 306.3% from the stock's current price. View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts .

How have LPTX shares performed in 2024?

Leap Therapeutics' stock was trading at $4.15 at the beginning of the year. Since then, LPTX stock has decreased by 32.5% and is now trading at $2.80. View the best growth stocks for 2024 here .

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LPTX earnings forecast .

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10.

What ETF holds Leap Therapeutics' stock?

Simplify Health Care ETF holds 529,326 shares of LPTX stock, representing 1.19% of its portfolio.

When did Leap Therapeutics' stock split?

Leap Therapeutics's stock reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA) , Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , Amarin (AMRN) , OPKO Health (OPK) , VYNE Therapeutics (VYNE) , Inovio Pharmaceuticals (INO) , Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL) .

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.91%). View institutional ownership trends .

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free LPTX Stock Alerts

$2.80

-0.16 (-5.41%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.77
▼
$3.04
50-Day Range: $2.14
▼
$3.44
52-Week Range: $1.24
▼
$10.20

Volume: 211,020 shs
Average Volume: 321,391 shs
Market Capitalization: $71.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.38

Get Leap Therapeutics alerts:

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 306.3% Upside
$11.38 Price Target
Short Interest: Bearish
4.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.08) to ($1.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

709th out of 911 stocks

Biotechnology Industry

23rd out of 34 stocks

3.5

Analyst's Opinion

Consensus Rating
Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Leap Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.87% of the float of Leap Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Leap Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Leap Therapeutics has recently increased by 0.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Leap Therapeutics does not currently pay a dividend.
Dividend Growth
Leap Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPTX.

2.0

News and Social Media Coverage

News Sentiment
Leap Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Leap Therapeutics this week, compared to 1 article on an average week.
Search Interest
12 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.30% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.46% of the stock of Leap Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Leap Therapeutics are expected to grow in the coming year, from ($2.08) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Leap Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Leap Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Leap Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LPTX Stock News Headlines

April 14, 2024 | americanbankingnews.com

Leap Therapeutics (NASDAQ:LPTX) Trading 4% Higher

April 11, 2024 | markets.businessinsider.com

Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | prnewswire.com

Leap Therapeutics Announces $40 Million Private Placement

March 26, 2024 | insidermonkey.com

5 Best Biotech Penny Stocks to Invest In

March 19, 2024 | markets.businessinsider.com

Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating

March 18, 2024 | investorplace.com

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023

March 18, 2024 | finanznachrichten.de

Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 18, 2024 | finance.yahoo.com

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 15, 2024 | finance.yahoo.com

LPTX Apr 2024 5.000 call

February 17, 2024 | finance.yahoo.com

LPTX Mar 2024 7.000 call

January 26, 2024 | markets.businessinsider.com

Outperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial Outcomes

January 17, 2024 | msn.com

Evolus, Leap Therapeutics among healthcare movers

January 16, 2024 | finance.yahoo.com

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

January 6, 2024 | markets.businessinsider.com

Optimism High as Leap Therapeutics’ Studies Suggest Potential for Significant Shareholder Value

January 4, 2024 | ca.finance.yahoo.com

LPTX Jun 2024 1.000 call

January 4, 2024 | ca.finance.yahoo.com

LPTX Mar 2024 1.000 call

January 3, 2024 | finance.yahoo.com

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024 | finance.yahoo.com

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

December 11, 2023 | finance.yahoo.com

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

November 21, 2023 | finance.yahoo.com

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

November 14, 2023 | markets.businessinsider.com

Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know

November 13, 2023 | finanznachrichten.de

Leap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2023 Financial Results

November 13, 2023 | benzinga.com

Recap: Leap Therapeutics Q3 Earnings

November 13, 2023 | finance.yahoo.com

Leap Therapeutics Reports Third Quarter 2023 Financial Results

September 5, 2023 | finance.yahoo.com

Leap Therapeutics to Participate at Upcoming Investor Conferences

See More Headlines

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:LPTX
CUSIP: N/A
CIK: 1509745
Web: www.leaptx.com
Phone: (617) 714-0360
Fax: N/A
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.38
High Stock Price Target: $17.50
Low Stock Price Target: $7.00
Potential Upside/Downside: +306.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -133.17%
Return on Assets: -90.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.64
Quick Ratio: 5.64

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 47.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.35 per share
Price / Book: 1.19

Miscellaneous

Outstanding Shares: 25,600,000
Free Float: 22,707,000
Market Cap: $71.68 million
Optionable: Optionable
Beta: 0.57

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Douglas E. Onsi J.D. (Age 55)
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Comp: $1.04M
Mr. Augustine J. Lawlor (Age 67)
Chief Operating Officer
Comp: $713.57k
Dr. Cynthia A. Sirard (Age 54)
Chief Medical Officer
Comp: $708.64k
Dr. Jason S. Baum Ph.D. (Age 45)
Chief Scientific Officer
Mr. Mark O'Mahony (Age 53)
Chief Manufacturing Officer
Ms. Christine M. Granfield (Age 56)
VP and Head of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings or view top-rated stocks.
What is Leap Therapeutics' stock price target for 2024?: 4 Wall Street research analysts have issued 1 year price targets for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $17.50. On average, they predict the company's share price to reach $11.38 in the next twelve months. This suggests a possible upside of 306.3% from the stock's current price.
View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts.
How have LPTX shares performed in 2024?: Leap Therapeutics' stock was trading at $4.15 at the beginning of the year. Since then, LPTX stock has decreased by 32.5% and is now trading at $2.80.
View the best growth stocks for 2024 here.
When is Leap Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LPTX earnings forecast.
How were Leap Therapeutics' earnings last quarter?: Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10.
What ETF holds Leap Therapeutics' stock?: Simplify Health Care ETF holds 529,326 shares of LPTX stock, representing 1.19% of its portfolio.

When did Leap Therapeutics' stock split?: Leap Therapeutics's stock reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Leap Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL).
Who are Leap Therapeutics' major shareholders?: Leap Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.91%).
View institutional ownership trends.
How do I buy shares of Leap Therapeutics?: Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial